FIELD: medicine.
SUBSTANCE: invention refers to Trecresan application for improving heart haemodynamics and reduction of metabolic disorders in treating the patients suffering arterial hypertension and obesity, and also its combinations with ATE inhibitors.
EFFECT: higher clinical effectiveness.
3 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PATIENTS WITH OBESITY AND ARTERIAL HYPERTENSION STATE CORRECTION | 2019 |
|
RU2729352C1 |
| METHOD OF CONDITION CORRECTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY CORRECTION | 2019 |
|
RU2740374C2 |
| AGENT INTENSIFYING THROMBOCYTE ACID LYPASE ACTIVITY | 2010 |
|
RU2429833C1 |
| AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
| AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
| METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
| MEDIATION INCREASING LEVEL OF LACTOFERRIN IN ORGANISM | 2012 |
|
RU2486894C1 |
| MEDICATION MODULATING CONCENTRATION OF FERRITIN IN BLOOD SERUM | 2012 |
|
RU2486895C1 |
| METHOD OF COMPLEX THERAPY OF OBESITY IN PATIENTS WITH ARTERIAL HYPERTENSION | 2015 |
|
RU2607186C1 |
| METHOD FOR PREDICTION OF MEDICAL-SOCIAL EFFECTIVENESS OF INTEGRATED TREATMENT IN PATIENTS WITH ARTERIAL HYPERTENSION | 2012 |
|
RU2522389C1 |
